Sort   by:  
 Page size 
MetabolomicsA blood-based metabolic signature for earlier detection of lung cancer

Metabolomic profiling was applied to 1,259 sera collected within five years of a lung cancer diagnosis and 8,470 non-case sera from ever-smoker participants in the Prostate Lung Colorectal and Ovarian (PLCO) Study to identify metabolic signatures for the earlier detection of lung cancer. We devel...

2026-08-20 | MTBLS15406 | MetaboLights
MetabolomicsNon-invasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer
Lung cancer remains the most common cause of cancer deaths worldwide, yet there is currently a lack of diagnostic noninvasive biomarkers that could guide treatment decisions. Small molecules (<1500 Da) were measured in urine collected from 469 lung cancer patients and 536 population controls using u...
2014-05-06 | MTBLS28 | MetaboLights
MetabolomicsNiacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Cell NAMPTi treatment)

NAMPT plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi...

2023-10-10 | MTBLS7251 | MetaboLights
MetabolomicsNiacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Mouse NAMPT targeted therapy)

NAMPT plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi...

2023-10-10 | MTBLS7252 | MetaboLights
MetabolomicsNiacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Mouse NAD targeted time-course)

NAMPT plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi...

2023-10-10 | MTBLS7253 | MetaboLights
MetabolomicsTemporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment
Lung cancer causes more deaths in men and women than any other cancer related disease. Currently, few effective strategies exist to predict how patients will respond to treatment. We evaluated the serum metabolomic profiles of 25 lung cancer patients undergoing chemotherapy ± radiation to evaluate t...
2017-01-19 | MTBLS200 | MetaboLights
MetabolomicsTargeting GSTZ1 sensitizes KRASG12C-mutant lung cancer cells by overcoming glutathione and glycolysis pathway rewiring

KRAS mutations are prevalent in lung cancer, but KRAS G12C inhibitors exhibit limited efficacy, partly due to metabolic adaptations, such as enhanced glutathione metabolism and increased glycolysis. Glutathione S-Transferase Zeta 1 (GSTZ1) is a metabolic enzyme that regulates cell metabolism. How...

2026-05-15 | MTBLS12791 | MetaboLights
MetabolomicsNon-targeted metabolomics reveals diagnostic biomarker in the plasma of patients with lung cancer

Lung cancer are malignant tumors with high incidence and mortality rates, and a 5-year survival rate that depends on the stage at the time of diagnosis. Screening methods for lung cancer are becoming increasingly diverse, but existing approaches lack sensitivity or specificity for early lesions, ...

2025-09-13 | MTBLS12985 | MetaboLights
MetabolomicsMFSD7C protects hemolysis-induced lung impairments by inhibiting ferroptosis

Hemolysis drives susceptibility to lung injury and predicts poor outcomes in diseases, such as malaria and sickle cell disease (SCD). However, the underlying pathological mechanism remains unknown. Here, we report that major facilitator superfamily domain containing 7C (MFSD7C) protects the lung ...

2024-09-06 | MTBLS9293 | MetaboLights
MetabolomicsSearching for Drug Synergy Against Cancer Through Polyamine Metabolism Impairment: Insight Into the Metabolic Effect of Indomethacin on Lung Cancer Cells
Non-small cell lung cancer (NSCLC) is the most lethal and prevalent type of lung cancer. In almost all types of cancer, the levels of polyamines (putrescine, spermidine, and spermine) are increased, playing a pivotal role in tumor proliferation. Indomethacin, a non-steroidal anti-inflammatory drug, ...
2021-02-08 | MTBLS873 | MetaboLights
Sort   by:  
 Page size